NCT00171587View on ClinicalTrials.gov

Study of the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Effects of Vatalanib in Combination With Capecitabine in Patients With Advanced Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

May 31, 2002

Primary Completion Date

March 31, 2007

Study Completion Date

March 31, 2007

Conditions
TumorsNeoplasm Metastasis
Interventions
DRUG

PTK787/ZK 222584 (vatalanib)

Trial Locations (1)

60637

University of Chicago, Chicago

Sponsors

Lead Sponsor

Novartis

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

Novartis

INDUSTRY